What are the core strategies in antimicrobial stewardship?

The two primary strategies are prospective audit with intervention and feedback (PAIAF) — pharmacist or ID physician review of prescriptions with recommendations — and formulary restriction with pre-authorisation, where certain antimicrobials require approval before dispensing. Supplementary strategies include de-escalation, IV-to-oral switch, dose optimisation, and biomarker-guided therapy (procalcitonin).

What metrics are used to measure antimicrobial use?

Defined Daily Dose (DDD) per 1,000 patient-days is the standard WHO metric for comparing antimicrobial use across facilities. Days of Therapy (DOT) per 1,000 patient-days is preferred in the US (CDC NHSN) as it is not affected by dose changes. Lower DDD or DOT with maintained clinical outcomes indicates effective stewardship.

Guide

Antimicrobial Stewardship

A clinical overview of antimicrobial stewardship programme (ASP) strategies, metrics, PK/PD dose optimisation, de-escalation, and resistance prevention — grounded in IDSA, ASHP, and CDC guidance.

Why Antimicrobial Stewardship?

Antimicrobial resistance (AMR) is one of the greatest threats to global health. The WHO warns that AMR could cause 10 million deaths annually by 2050 without action. In the US, the CDC estimates 2.8 million antibiotic-resistant infections and 35,000 deaths per year. Antimicrobial stewardship programmes (ASPs) are evidence-based, cost-effective interventions that reduce inappropriate use — the primary driver of resistance development.

US federal law (CMS Conditions of Participation) has required hospitals to have ASPs since 2020. The Joint Commission MM.09.01.01 standard further specifies antimicrobial stewardship requirements for accredited hospitals.

Core ASP Strategies

The IDSA/SHEA antimicrobial stewardship guidelines and ASHP stewardship resources identify two primary and several supplementary strategies:

Primary

Prospective Audit with Intervention and Feedback (PAIAF)

Pharmacist or ID physician reviews ongoing antimicrobial prescriptions and provides real-time recommendations (change agent, dose, duration, route). Most studied and evidence-based strategy. Associated with 20–30% reduction in antimicrobial use without adverse outcomes.

Primary

Formulary Restriction and Pre-authorisation

Certain antimicrobials (carbapenems, daptomycin, caspofungin) require approval from ID or pharmacy before dispensing. Produces immediate reductions in restricted agent use. Risk of delays for critically ill patients; requires 24/7 availability.

IV-to-Oral Switch

Transition from IV to oral antimicrobials when patient can tolerate oral medications and the oral agent has adequate bioavailability. Key agents: fluoroquinolones (near 100% oral F), linezolid, metronidazole, clindamycin. Reduces catheter-related infections, length of stay, and cost. IDSA supports early IVOST.

Biomarker-Guided Therapy

Procalcitonin (PCT)-guided algorithms reduce antibiotic duration in lower respiratory tract infections without increased mortality. PCT <0.25 µg/L strongly suggests non-bacterial aetiology; PCT-guided discontinuation is endorsed by SCCM in sepsis.

Rapid Diagnostics

Blood culture multiplex PCR panels (e.g., BioFire BCID), MALDI-TOF for rapid organism identification, and rapid AST methods enable faster de-escalation and reduce time to appropriate therapy by 12–24 hours in bacteraemia.

Antibiotic Time-Out

A structured review at 48–72 h post-initiation to assess: (1) Is antibiotics still indicated? (2) What does the culture show? (3) Can de-escalate? (4) What is the planned duration? Embedded in nursing notes or electronic health record prompts.

PK/PD Dose Optimisation

Antimicrobial pharmacodynamics describes the relationship between drug exposure and bacterial kill. Three PK/PD indices link exposure to the MIC:

T>MIC

Time-dependent

Efficacy correlates with the percentage of the dosing interval that free drug concentration exceeds the MIC. Optimise by: shorter intervals, continuous/extended infusion. Examples: beta-lactams (penicillins, cephalosporins, carbapenems), azithromycin.

Cmax/MIC

Concentration-dependent

Efficacy correlates with peak concentration relative to MIC. Optimise with: high doses, longer intervals. Once-daily aminoglycosides (gentamicin, tobramycin) use this principle — peak 8–10× MIC. Examples: aminoglycosides, fluoroquinolones (also AUC/MIC).

AUC/MIC

Exposure-dependent

Efficacy correlates with total drug exposure relative to MIC. Target AUC/MIC 400–600 for vancomycin (MRSA, MIC 1 mg/L). Fluoroquinolones: AUC/MIC >125 for gram-negative infections. ASHP/IDSA vancomycin 2020.

Extended infusion of beta-lactams

For beta-lactams, T>MIC is optimised by prolonged infusion. Piperacillin-tazobactam 4.5 g over 4 h (vs 30 min) achieves higher T>MIC for organisms with elevated MICs, particularly Pseudomonas aeruginosa. Meta-analyses and Monte Carlo simulations support extended/continuous infusion for susceptible gram-negatives. See Extended infusion beta-lactam review (NCBI).

Measuring Antimicrobial Use

Metric	Definition	Numerator	When preferred
DDD	Defined Daily Dose per 1,000 patient-days	Total grams dispensed / WHO-defined DDD	International comparisons, benchmarking; not affected by patient weight
DOT	Days of Therapy per 1,000 patient-days	Number of days any dose of agent given	US (CDC NHSN standard); preferred because not affected by dose changes
LOT	Length of Therapy	Days from first to last dose of any antimicrobial	Captures total treatment course regardless of agents used
SAR	Standardised Antibiotic Ratio (NHSN)	Observed DOT / predicted DOT based on case-mix	Hospital benchmarking accounting for patient complexity

WHO DDD values are available at whocc.no. CDC NHSN antimicrobial use and resistance module guidance at cdc.gov/nhsn.

De-escalation and Duration Optimisation

De-escalation is the cornerstone of ASP — narrowing empirical broad-spectrum therapy once culture and sensitivity results are available. Evidence consistently shows de-escalation does not worsen mortality in sepsis and reduces adverse effects and resistance selection.

Review at 48–72 h — "Antibiotic time-out." Has the clinical picture changed? Are cultures back? Is antibiotics still indicated?

Narrow based on culture — If blood culture grows MSSA, stop vancomycin and start oxacillin or cefazolin. If cultures are negative and clinical improvement, consider stopping altogether.

Shortest effective duration — Most infections are over-treated. Evidence-based duration benchmarks: community-acquired pneumonia 5 days (IDSA/ATS CAP guidelines); uncomplicated urinary tract infection 3–5 days; non-bacteraemic gram-negative bacteraemia 7–14 days.

Document the plan — Antibiotic stop date, planned duration, and indication should be in the medical record at initiation. Electronic decision support (EDS) can prompt review and enforce stop orders.

FAQ

What is antimicrobial stewardship?

A coordinated programme to optimise antimicrobial use: right drug, dose, route, and duration — improving clinical outcomes, reducing adverse effects, and slowing resistance development.

What are the core ASP strategies?

Primary: (1) prospective audit with intervention and feedback (PAIAF), (2) formulary restriction and pre-authorisation. Supplementary: IV-to-oral switch, biomarker-guided therapy, rapid diagnostics, and antibiotic time-out.

What metrics measure antimicrobial use?

DDD (Defined Daily Dose) per 1,000 patient-days (WHO standard, international benchmarking) and DOT (Days of Therapy) per 1,000 patient-days (CDC NHSN preferred US metric). Lower values with maintained outcomes indicate effective stewardship.

What is PK/PD optimisation in antimicrobial stewardship?

Matching dosing regimen to the drug's pharmacodynamic target: T>MIC for beta-lactams (extended infusion), Cmax/MIC for aminoglycosides (once-daily), and AUC/MIC for vancomycin (AUC/MIC 400–600) and fluoroquinolones.